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Abstract
LEOPARD syndrome (LS, OMIM 151100) is a rare multiple congenital anomalies condition, mainly
characterized by skin, facial and cardiac anomalies. LEOPARD is an acronym for the major features
of this disorder, including multiple Lentigines, ECG conduction abnormalities, Ocular
hypertelorism, Pulmonic stenosis, Abnormal genitalia, Retardation of growth, and sensorineural
Deafness. About 200 patients have been reported worldwide but the real incidence of LS has not
been assessed. Facial dysmorphism includes ocular hypertelorism, palpebral ptosis and low-set ears.
Stature is usually below the 25th centile. Cardiac defects, in particular hypertrophic cardiomyopathy
mostly involving the left ventricle, and ECG anomalies are common. The lentigines may be
congenital, although more frequently manifest by the age of 4–5 years and increase throughout
puberty. Additional common features are café-au-lait spots (CLS), chest anomalies, cryptorchidism,
delayed puberty, hypotonia, mild developmental delay, sensorineural deafness and learning
difficulties. In about 85% of the cases, a heterozygous missense mutation is detected in exons 7, 12
or 13 of the PTPN11 gene. Recently, missense mutations in the RAF1 gene have been found in two
out of six PTPN11-negative LS patients. Mutation analysis can be carried out on blood, chorionic
villi and amniotic fluid samples. LS is largely overlapping Noonan syndrome and, during childhood,
Neurofibromatosis type 1-Noonan syndrome. Diagnostic clues of LS are multiple lentigines and
CLS, hypertrophic cardiomyopathy and deafness. Mutation-based differential diagnosis in patients
with borderline clinical manifestations is warranted. LS is an autosomal dominant condition, with
full penetrance and variable expressivity. If one parent is affected, a 50% recurrence risk is
appropriate. LS should be suspected in foetuses with severe cardiac hypertrophy and prenatal DNA
test may be performed. Clinical management should address growth and motor development and
congenital anomalies, in particular cardiac defects that should be monitored annually. Hypertrophic
cardiomyopathy needs careful risk assessment and prophylaxis against sudden death in patients at
risk. Hearing should be evaluated annually until adulthood. With the only exception of ventricular
hypertrophy, adults with LS do not require special medical care and long-term prognosis is
favourable.
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Leopard syndrome (LS, OMIM 151100) is named based
on an acronym, mnemonic for the major features of this
disorder: multiple Lentigines, ECG conduction abnormal-
ities, Ocular hypertelorism, Pulmonic stenosis, Abnormal
genitalia, Retardation of growth, and sensorineural Deaf-
ness [1,2]. This disease was also known as Multiple Lentig-
ines syndrome, Cardio-cutaneous syndrome, Moynahan
syndrome, Lentiginosis profusa and Progressive Cardio-
myopathic Lentiginosis.
Historical notes
LS was first reported by Zeisler and Becker in 1936, in a
24-year-old woman presenting with multiple lentigines,
increasing in number from birth to puberty, pectus carina-
tum, hypertelorism and prognathism [3]. A few decades
later, Gorlin et al. reviewed this disorder and coined the
LEOPARD acronym supporting the concept of a more
generalised condition [1].
Epidemiology
LS is a rare condition, but the exact birth prevalence is
unknown. Not less than 200 patients have been reported
and two reviews published [1,4]. Within the group of the
so called 'neuro-cardio-facial-cutaneous' (NCFC) syn-
dromes, LS is probably the second most common disorder
after Noonan syndrome (NS) [5]. However, LS is likely
underdiagnosed or misdiagnosed as many of its features
are mild and the correct diagnosis might be missed in the
absence of lentiginosis.
Clinical description
LS is characterised by the presence of multiple lentigines,
although these patients are showing a wide spectrum of
features with marked variation in expression [1,2,4,6]. As
mnemonically suggested by the acronym, the main fea-
tures include multiple lentigines, facial dysmorphisms,
cardiac anomalies, electrocardiographic (ECG) conduc-
tion abnormalities, retardation of growth, abnormal gen-
italia and sensorineural deafness.
Facies
Facial dysmorphisms are characteristic and change con-
siderably with age, being less striking at birth and in the
first infancy, with the most characteristic features becom-
ing evident during childhood (Figure 1). Dysmorphic fea-
tures can occur or be only mildly expressed in the
newborns and infants [7]. Hypertelorism is virtually
present in all cases, and flat nasal bridge and dysmorphic
ears in about 87% of the patients. Additional, less fre-
quent, features include palpebral ptosis, thick lips and
low-set ears with overfolded helix (50%), large and
everted ears, pterygium colli or redundant neck skin
(37%) [7]. Adult patients usually manifest hypertelorism,
palpebral ptosis, low-set ears, deep nasal-labial folds and
premature skin wrinkling.
Cardiovascular system
Electrocardiographic anomalies and progressive conduc-
tion anomalies are the most common heart defects [4,6-
8]. A superiorly oriented mean QRS axis in the frontal
plane is frequently observed, even in the absence of struc-
tural cardiac abnormalities, and does represent a useful
diagnostic handle. A cardiological review indicated that
ECG abnormalities occur in about 75% of the patients,
including left or biventricular hypertrophy in 46% of
them, often in association with q waves (19%), prolonged
QTc (23%) and repolarisation abnormalities (42%) [8].
Conduction defects are found in 23% of the patients and
p wave abnormalities in 19%. On the whole, about 70%
of LS individuals display cardiac defects [[8]; personal
observation]. Previous reports suggested that pulmonary
valve stenosis (PVS), with or without dysplasia, is the
most common defect (40%) [4,6]. However, current data
points to a consistently lower figure for this defect (10–
20%) [8,9]. Conversely, hypertrophic cardiomyopathy
(HCM) is the most frequent anomaly and represents the
only life-threatening problem in these patients. HCM,
which in general is asymmetric and involves the left ven-
tricle, is detected in up to 80% of the subjects with cardiac
defect, and may associate with significant left ventricular
outflow tract obstruction in up to 40% of the cases [[8-
10]; personal data]. Fatal events and sudden death have
been reported in LS patients with HCM [7,8,11,12]. HCM
can be congenital, but frequently manifests during the sec-
ond infancy [7,8,12]. The onset of HCM usually precedes
multiple lentigines, but the hypertrophic process may
start or often worsen in parallel with lentigines appear-
Five year-old girl with multiple lentigines, cafè-au-lait spots and dysm rphic featuresigur  1
Five year-old girl with multiple lentigines, cafè-au-lait spots 
and dysmorphic features. 1A. Note the hyperthelorism, pto-
sis, blue eyes and low set dysmorphic ears. 1B. Note the 
short neck with pterigium colli, teletelia, pectus excavatum 
and diffuse lentiginosis on the trunk.Page 2 of 8
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cal abnormalities have been found in up to 42% of cases
[8]. Less frequent heart defects are atrial and atrioventricu-
lar septal defects, coronary artery abnormalities, apical
aneurysm and non compaction of the left ventricle, mul-
tiple ventricular septal defects, isolated left ventricular
enlargement and endocardial fibroelastosis [[6,8]; per-
sonal observation].
Skin
Multiple lentigines are a distinct feature of LS, even if they
may be absent in young patients and, quite exceptionally
also in subjects older than 5 years [[10]; personal observa-
tion] (Figure 1 and 2). Lentigines are flat, black-brown
macules, dispersed mostly on the face, neck, and upper
part of the trunk, but sparing the mucosae. In general, len-
tigines appear at 4–5 years and increase into the thou-
sands until puberty, independently from sun exposure
Skin features of LS individual at different agesFigure 2
Skin features of LS individual at different ages. 2A: Numerous lentigines in the upper part of the trunk in a 2 year old child with 
a PTPN11 gene mutation. 2B. Lentigines and a large cafè-au-lait spot (28 year-old female patient). 2C. A 28 year old female 
patient with thousands of lentigines scattered all over the neck and back. Note the pterigium colli. 2D. Multiple lentigines on 
the lower leg (37 year-old male patient).Page 3 of 8
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characterised by pigment accumulation in the dermis and
deeper epidermal layers, with increased number of
melanocytes per unit skin area. The cafè-au-lait spots (CLS),
occurring in about half of the patients, are similar to those
found in Neurofibromatosis type 1 (NF 1), although they
appear much darker in the dark skinned individuals (Fig-
ure 2). CLS may be congenital or precede the appearance
of lentigines [[10]; personal observation]. Occasional
hypopigmented skin areas may also be observed [13].
Weight and length
Birth weight is normal or above the average in one third
of the newborns [10]. Subsequently, LS patients show
retardation of growth, with 25% of cases below the 3rd
centile in height and 85% of adults below the 25th centile
[[4,14]; personal observation].
Skeletal anomalies
Thorax anomalies, including broad chest, pectus carina-
tum or excavatum are found in up to 75% of the new-
borns [10]. Mandibular prognathism, winging of the
scapulae, scoliosis, joint hyperflexibility and other find-
ings are less common [14].
Genital and urinary tract anomalies
Bilateral cryptorchidism occurs in about 50% of males,
but hypospadia and genital hypoplasia are also frequent.
Delayed puberty and hypoplastic ovary have been
reported in females. More cases are transmitted through
affected mothers suggesting a reduced male fertility. Renal
anomalies, including horseshoe kidney, are rare [4,10].
Hearing loss
Sensorineural deafness occurs in about 15–25% of
patients [6,9]. Most cases are diagnosed at birth or during
childhood, but deafness may develop also later in life.
Neurological abnormalities
Hypotonia is common in the newborn and can result in
delayed psychomotor development [10]. Mild learning
difficulties are reported in about 30% of the cases, while
mental retardation is rare [[4,10]; personal observation].
Tumours
Haematological complications, such as myelodysplasia,
acute myelogenous leukaemia and neuroblastoma, have
been described in a few patients [4,15,16]. Malignant
melanoma was diagnosed in a patient with a germline
PTPN11 and a somatic BRAF mutation [17]. Bilateral
choristomas have been reported in a 5-year-old girl [18].
Aetiology
LS may be sporadic or inherited as an autosomal domi-
nant fully penetrant trait. In approximately 85% of the
patients with a definite diagnosis of LS, a missense muta-
tion is found in the PTPN11 gene, located on chromo-
some 12q24.1 [9,19]. The PTPN11 gene encodes for the
SRC homology 2 (SH2) domain-containing PTPase
(SHP2) protein, characterised by two tandemly arranged
SH2 (N-SH2 and C-SH2) domains and one protein tyro-
sine phosphatase (PTP) domain. SHP2 functions as a
cytoplasmic signalling transducer downstream of multi-
ple receptors for growth factors, cytokines and hormones,
with a particular role through the RAS-mitogen activated
protein kinase (MAPK) pathway [20,21]. To the best of
our knowledge, 11 different missense PTPN11 mutations,
in exon 7, 12 and 13 (Tyr279Cys/Ser, Ala461Thr,
Gly464Ala, Thr468Met/Pro, Arg498Trp/Leu, Gln506Pro,
and Gln510Glu/Gly), have been reported so far, two of
which (Tyr279Cys and Thr468Met) occur in about 65% of
the cases [[9,10,22-29], personal data]. Germinal muta-
tions in the PTPN11 gene are also responsible for about
40–50% of Noonan (NS) and Noonan-like/Multiple
Giant Cell lesions syndrome cases [30,31]. Known
changes appear to be exclusive for NS or LS, leading to
specific genotype-phenotype correlations between these
two disorders [23,31]. Among patients with PTPN11
mutations, an association between exon 7 and 12 muta-
tions and HCM, and between exon 8 mutations and PVS,
has been established [23]. LS patients without PTPN11
mutations show a higher prevalence of ECG abnormali-
ties and left ventricle hypertrophy [8]. Analyses of the nat-
ural history of HCM in LS patients with different
genotypes indicate that patients without PTPN11 muta-
tions show a higher frequency of family history of sudden
death, increased left atrial dimensions, bradyarrhythmias
and other adverse arrhythmic and nonarrhythmic events
[12]. Mutations affecting exon 13 in the PTPN11 gene are
often associated with an important cardiac phenotype,
characterised by rapidly progressive severe biventricular
obstructive HCM, often with prenatal onset, and with seri-
ous cardiac complications during follow-up (heart failure,
septal myectomy, and sudden death) [12,28,32]. Analysis
of personal cohorts of LS patients indicate that mutation
of the Thr468 residue is less frequently associated with
short stature, compared to mutation of the Tyr279 residue
(26% vs. 47%), in which also deafness is more common
(24% vs. 9%) [personal data]. This data confirm a previ-
ous observation of less adverse effects of the Thr468Met
mutation on body growth and cardiac development, with
lower prevalence of PVS in these patients [33].
Although LS and NS are clinically overlapping conditions,
nosological splitting is well supported by distinct func-
tional effects of the disease causing mutation: gain of
function in NS and reduced protein tyrosine phosphatase
activity in LS, suggestive of a dominant-negative effect
[34,35].Page 4 of 8
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[36], and recently confirmed by the identification of RAF1
gene mutations in two out of six PTPN11 mutation nega-
tive LS patients [37]. RAF1 protein is one of the three
mammalian RAF isoforms (ARAF, BRAF and CRAF or
RAF1), threonine-serine protein kinases with nonredun-
dant developmental functions, acting downstream of RAS
[38]. RAF1 gene mutations are also responsible for a sub-
set of NS, 75% of which develop HCM [37,39]. The two
LS subjects carrying the Leu613Val and Ser257Leu
changes disclosed a full blown LS phenotype, with multi-
ple lentigines, CLS, HCM and delayed puberty [37]. Pan-
dit et al. investigated the functional effect of different
RAF1 mutants, including the Leu613Val change, and
showed that those associated with HCM had increased
kinase activity and enhanced ERK activation [37]. These
data reinforce the role of increased RAS signalling in car-
diomyocyte hypertrophy pathogenesis and suggest that LS
pathogenesis should not be simply related to a reduced
RAS signal transduction [37,40].
About 5% of LS patients of the reported series do not have
PTPN11 or RAF1 mutations. Analysis of additional genes
encoding for member or the RAS pathway will likely
expand the LS genetic heterogeneity.
Distinct missense PTPN11 gene mutations occur as
somatic events in myeloid or lymphoid malignancies
[[34]; Cosmic database]. Both the spectrum and the distri-
bution of these PTPN11 mutations are different from
those documented in LS and related disorders.
Diagnosis and differential diagnosis
LS is a rare autosomal dominant disease, with high pene-
trance and marked variable expression, mainly character-
ised by short stature, facial dysmorphisms, cardiac
anomalies and hyperpigmented skin lesions, specifically
multiple lentigines and CLS [1,2,6]. According to Voron et
al., clinical diagnosis of LS may be suspected in the pres-
ence of multiple lentigines and two cardinal features [4].
In the absence of lentiginosis, three features in the patient
and the presence of an affected close relative are diagnos-
tic. Since some features manifest with advancing age, the
diagnosis may be problematic in very young patients with
only partial phenotypes. However, molecular testing is
supportive in this difficult task [9]. Digilio et al. suggested
that diagnosis of LS in the first months of age can be clin-
ically suspected in the presence of three main features,
including HCM, distinct facial dysmorphisms and CLS
[10].
LS is one of the so called 'neuro-cardio-facial-cutane-
ous'(NCFC) syndromes [5], which include some overlap-
ping disorders, such as NS, Neurofibromatosis type 1,
Costello syndrome, Cardiofaciocutaneous syndrome and
LS itself, all caused by mutations in some components of
the Ras signalling pathway. These subjects display facial
anomalies, heart defects and growth retardation, often
associated with skin, skeletal and genital anomalies, and
variable degree of mental retardation. In addition, each of
these conditions present a few distinct features that are
useful handles for differential diagnosis.
Except for its most striking feature, i.e. the multiple lentig-
ines, LS largely overlaps with NS [41,42]. While NS
patients show more conspicuous facial features in infancy
and childhood, PVS (single-ventricle physiology) is the
most frequent cardiac defect in this condition, and skin
anomalies and deafness have been rarely reported. Con-
versely, diagnostic clues of LS are the cutaneous manifes-
tations, such as CLS and multiple lentigines, HCM and
deafness. The phenotypic overlap between NS and LS may
complicate the differential diagnosis in young individuals
who have not yet developed lentigines. Molecular diagno-
sis and long term follow-up are critical in these individu-
als. In fact, re-examination later in life may reveal the
presence of CLS or lentigines, as for a patient with the
Tyr279Cys mutation reported by Tartaglia et al. [31,43].
Likewise, detection of a LS-related mutation should shift
the diagnosis toward this condition, as suggested by Dig-
ilio et al. for the patient reported by Takahashi and col-
leagues [8,28,32].
LS also displays an important phenotypic overlap with
Neurofibromatosis-Noonan syndrome (NFNS), a clinical
entity manifesting with the association of facial and car-
diac characteristics of NS with clinical features of neurofi-
bromatosis 1, including CLS, neurofibromas, central
nervous system and skeletal anomalies [44,45]. NFNS is
largely caused by NF1 gene mutations [46]. Nevertheless,
NFNS may have different potential aetiologies and NFNS
phenotype has been described also in patients with muta-
tions in both the NF1 and PTPN11 genes [47] as well as in
neurofibromatosis 1 (NF1) patients with Noonan-like
features [48,49]. In addition, patients with NS-related
gene mutations can have pigmentary skin manifestations
similar to those present in neurofibromatosis 1. Muta-
tion-based differential diagnosis in patients with border-
line clinical manifestations is warranted [50].
Genetic counselling
LS is caused by heterozygous missense mutations in auto-
somal genes. Familial cases are commonly reported, and
prevalence of transmitting mothers might be related to
reduced male fertility. Genetic counselling should
include:
• revision of a three generation family tree, with specific
enquiries for skin and cardiac anomalies, short stature
and learning difficulties;Page 5 of 8
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schooling;
• examination of growth parameters, facial dysmor-
phisms, skin, skeleton, joints, heart and external genitalia;
• complete clinical and cardiological examination of par-
ents, inclusive of echocardiogram and ECG, if possible;
• revision of natural history of the condition, its manifes-
tation and clinical variability, occurrence and recurrence
risks, and the eventual recommendation for clinical and
molecular investigations to confirm the diagnosis;
• management and follow-up, inclusive of available treat-
ments and interventions.
If one of the parents is affected, a 50% recurrence risk is
appropriate. Germinal mutations and autosomal recessive
inheritance have not been reported so far. Accordingly, in
case of identified de novo mutation in sporadic patients,
the recurrence risk for siblings is marginal. Molecular
investigation should take into account the PTPN11 gene
screening first, and then the RAF1 gene screening in
PTPN11-negative individuals.
Antenatal diagnosis
The prenatal differential diagnosis between NS and LS
may be extremely difficult. LS should be suspected in foe-
tuses with a normal karyotype and HCM. If LS is sus-
pected, physical examination of the parents is indicated. If
one parent is affected, obstetric ultrasound at different
timings and foetal echocardiography at 20 weeks' of ges-
tations is indicated. A DNA test for mutation analysis can
be carried out on chorionic villi or amniotic fluid samples.
Management, treatment and prognosis
Clinical management, follow-up and treatment of LS
patients greatly overlaps that of NS [41,42]. However, a
few issues need to be addressed differently, taking into
account the specific clinical problems and needs of LS
individuals. Baseline studies at diagnosis should include a
complete clinical examination, cardiological, genitouri-
nary and neurological evaluations and hearing assess-
ment. Laboratory studies should include molecular
analysis of the PTPN11 and RAF1 genes.
In general, long-term prognosis of LS patients is favoura-
ble. In case of cardiac anomalies at diagnosis, a periodic
assessment should be performed as recommended by the
cardiologist. Otherwise, a complete cardiological assess-
ment should be performed annually and particularly at
the appearance of multiple lentigines. Mild PVS has a
good prognosis, while severe valvular dysplasia of the pul-
monary valve may recommend valvulotomy or valvulec-
tomy [8]. As suggested by Limongelli et al., pathologic and
clinical findings may be similar in familial HCM and left
ventricular hypertrophy associated to LS [8]. Accordingly,
LS patients with ventricular hypertrophy may follow
familial HCM algorithms [51]. A beta-blockade or cal-
cium channel blockers therapy could be indicated in the
case of a significant gradient between the left ventricle and
the aorta. In the absence of any improvement, surgical
removal of the left ventricular outflow obstruction is indi-
cated. Fatal events occurring in patients with HCM recom-
mend careful risk assessment and prophylaxis against
sudden death in patients at risk [8,12,13]. Isolated con-
duction defects should be monitored annually and treated
as in the general population. Annual hearing assessment
should be performed until adulthood and hearing aids
indicated, if needed. During follow-up, growth parame-
ters should be monitored as in NS [41,42]. If growth hor-
mone (GH) therapy is started, the cardiac status should be
ongoing assessed, in particular in the presence of HCM. In
the case of multiple lentigines or CLS, total UVA-UVB pro-
tection should be indicated. Genitourinary, musculoskel-
etal, neurological and orthodontic anomalies should be
monitored and treated as for NS [41,42]. In the presence
of developmental delay or difficulties at school, an infant
stimulation program and alternate teaching method
should be initiated. Hypotonia usually is benefiting of
physical and occupational therapies. On the whole, most
adults with LS do not require special medical care. Males
with cryptorchidism in childhood may have fertility prob-
lems in adulthood.
Unresolved questions
The LS phenotype is extremely heterogeneous, ranging
from adults with mild facial features and multiple lentigi-
nes, to patients with severe HCM, mental retardation,
deafness and additional defects. Genotype-phenotype
correlation analysis and functional studies are providing
answers to these questions. In early childhood and before
the appearance of lentigines, diagnosis of LS is sometimes
difficult because of the overlap with NS and NFNS. In
these patients, a mutation-based diagnosis is recom-
mended.
Presence of patients without PTPN11 and RAF1 mutations
further expand genetic heterogeneity of LS and points
towards other genes likely involved in the same RAS-
MAPK pathway.
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